Overview

Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication

Status:
Recruiting

Trial end date:
2022-04-13

Target enrollment:
0

Participant gender:
All

Summary

This study aims to evaluate the efficacy of vonoprazan compared with esomeprazole as first-line treatment for Helicobacter Pylori(Hp) eradication, as well as the safety and economic benefits.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Treatments:

Amoxicillin
Bismuth
Esomeprazole
Furazolidone

Criteria

Inclusion Criteria:

1. Helicobacter pylori-positive participants determined by ¹³C-urea breath test, ¹⁴C-urea
breath test, HE stain or bacterium culture

2. With no historical treatment for helicobacter pylori infection.

Exclusion Criteria:

1. Administration of antibiotics, bismuth in 4 weeks prior to inclusion or antacids
including H2 receptor antagonist, proton pump inhibitor and potassium-competitive acid
blocker in 2 weeks prior to inclusion

2. Active peptic ulcer with complications such as hemorrhage, perforation, obstruction,
cancerization, etc.

3. With previous esophageal or gastric surgery

4. With severe systemic diseases, major organ like heart, lung, brain diseases, liver or
kidney insufficiency, malignant tumor or other diseases

5. Allergy to any of the study drugs

6. Pregnancy or in lactation

7. Participated in other research within 3 months，cannot express his/her own ideas
correctly or cannot cooperate with the researcher